for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Advaxis, Inc.

ADXS.OQ

Latest Trade

0.51USD

Change

0.00(0.00%)

Volume

22,184

Today's Range

--

 - 

--

52 Week Range

0.21

 - 

10.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.51
Open
0.00
Volume
22,184
3M AVG Volume
129.87
Today's High
--
Today's Low
--
52 Week High
10.79
52 Week Low
0.21
Shares Out (MIL)
24.71
Market Cap (MIL)
9.86
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Advaxis Inc Earnings Release

Latest Developments

More

Advaxis Inc - Received Written Notice From Staff Of Listing Qualifications Department Of Nasdaq Stock Market

Advaxis Reports Qtrly Loss Per Share $1

Advaxis Inc Files For Offering Of Up To 11.8 Million Shares Of Common Stock And Warrants To Purchase Up To 8.9 Million Shares Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Advaxis, Inc.

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Industry

Biotechnology & Drugs

Contact Info

305 College Rd E

+1.732.5451590

https://www.advaxis.com/

Executive Leadership

David Sidransky

Independent chairman of the Board

Kenneth A. Berlin

President, Chief Executive Officer, Director

James P. Patton

Independent Non-Executive Vice Chairman of the Board

Molly Henderson

Chief Financial Officer, Executive Vice President

Roni A. Appel

Independent Director

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-31.200

2017

-34.650

2018

-19.350

2019(E)

-2.370
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.45
Price To Book (MRQ)
0.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-50.34
Return on Equity (TTM)
-42.70

Latest News

Latest News

BRIEF-Advaxis Announces Executive Leadership Changes

* ADVAXIS INC - KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Advaxis Reports Q1 Loss Per Share $0.49

* ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB)

BRIEF-Advaxis Prices $20.0 Mln Public Offering Of Common Stock

* ADVAXIS PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Advaxis Announces Proposed Public Offering Of Common Stock

* ADVAXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31

* ADVAXIS INC SAYS EXPECTS TO REPORT THAT IT HAD $59.4 MILLION OF CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JANUARY 31, 2018 - SEC FILING Source text: (http://bit.ly/2BHztlx) Further company coverage:

BRIEF-Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union

* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION

BRIEF-Advaxis Says Expects Its Current Cash Position Will Be Sufficient To Fund Its Business Plan Into Fiscal 2019

* ADVAXIS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BRIEF-Advaxis Q4 loss per share $1.74

* Advaxis reports business update and third quarter 2017 results

Advaxis CEO Daniel O'Connor resigns

Cancer immunotherapy developer Advaxis Inc said on Thursday Daniel O'Connor stepped down from his position as the company's chief executive and its board.

BRIEF-Advaxis names ‍Anthony Lombardo interim CEO

* Advaxis inc - Anthony Lombardo named interim chief executive officer

BRIEF-Advaxis says confirms is on track to initiate clinical studies of ADXS-NEO later this year

* Company confirmed that it is on track to initiate clinical studies of ADXS-NEO later this year

BRIEF-Advaxis and Bristol-Myers Squibb announce clinical collaboration to evaluate ADXS-DUAL and Opdivo in metastatic cervical cancer

* Advaxis and Bristol-Myers Squibb announce clinical collaboration to evaluate ADXS-DUAL and opdivo (nivolumab) in metastatic cervical cancer

BRIEF-Advaxis Inc- European Medicines Agency issued an advanced therapy medicinal product certificate

* Advaxis Inc - European Medicines Agency issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data Source text for Eikon: Further company coverage:

BRIEF-Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO

* Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO

BRIEF-Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy

* Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy

BRIEF-Advaxis files for common stock offering of up to $250 mln

* Advaxis Inc files for common stock offering of up to $250 million - SEC filing Source text: (http://bit.ly/2lxVKqw) Further company coverage:

BRIEF-Advaxis to present phase 1 combination data, new preclinical data using Axal

* Advaxis to present phase 1 combination data and new preclinical data using AXAl at upcoming society for immunotherapy of cancer (SITC) 2016 annual meeting Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up